We evaluated the in vitro activity of this compound against wild-type and echinocandin-resistant (ER) isolates containing mutations in the FKS gene (s) of Candida spp. and Aspergillus spp. MK-3118 demonstrated enhanced efficacy for most C. albicans and C. glabrata ER isolates relative to caspofungin, with decreased MICs and half-maximal inhibito...

Ibrexafungerp (MK 3118) 是一种具有口服活性的 β-1,3-葡聚糖 合成抑制剂，具有有效的抗真菌活性。 Ibrexafungerp 可用于研究念珠菌 (Candida)和曲霉菌 (Aspergillus) 感染。 * Please select Quantity before adding items. Ibrexafungerp (MK 3118) is an orally active β-1,3-glucan synthesis inhibitor, with potential antifungal activity.

Fixed stainless steel bezel set with white Swarovski crystals. Mother of pearl dial with silver-tone hands and stick hour markers. Quartz movement. Scratch resistant mineral crystal. Solid case back. Case diameter: 36 mm. Case thickness: 10.5 mm. Push button deployment clasp. Water resistant at 30 meters / 100 feet. Functions: hour, minute, second.

MK-3118 (24 h of incubation and 50% EC) was active against all the species tested and displayed similar potency to caspofungin (using CLSI BMD) against C. albicans (MIC90, 1 and 2 mg/L, respectively), C. tropicalis (1 and 1 mg/L, respectively), C. parapsilosis (0.5 and 0.5 mg/L, respectively) and C. krusei (2 and 1 mg/L, respectively), but was 8...

MK-3118, a glucan synthase inhibitor derived from enfumafungin, and comparator agents were tested against 71 Aspergillus spp., including itraconazole-resistant strains (MIC, ≥ 4 μg/ml), using CLSI and EUCAST reference broth microdilution methods.

Ibrexafungerp 柠檬酸盐（MK-3118；SCY078；MK3118；SCY-078；Brexafemme）是 Ibrexafungerp 的柠檬酸盐，是一种 β-1,3-葡聚糖合成抑制剂，被批准作为治疗外阴阴道念珠菌病 (VVC) 的抗真菌药物（阴道酵母菌感染）。

2015年1月27日 · Derivatives of enfumafungin are novel orally bioavailable glucan synthase inhibitors. We performed an in vivo pharmacodynamic (PD) evaluation with a novel enfumafungin derivative, SCY-078 (formerly MK-3118), in a well-established neutropenic murine model of invasive candidiasis against C. albicans, C. glabrata, and C. parapsilosis.

Ibrexafungerp (originally known as MK-3118) is a semi-synthetic, orally bioavailable antifungal derivative of the echinocandin enfumafungin [1, 2]. Echinocandins are...

MK-3118 is an orally active, semisynthetic derivative of the natural product enfumafungin with in vitro and in vivo activity against Aspergillus spp. ( 18 – 22 ). MK-3118 and other derivatives of enfumafungin are potent inhibitors of fungal GS, yet these compounds are structurally distinct from the echinocandins ( 20 – 22 ).